PubMed:26010427 JSONTXT

{"project":"Linmchun_800_3","denotations":[{"id":"T1","span":{"begin":20,"end":47},"obj":"CI"},{"id":"T10","span":{"begin":1366,"end":1388},"obj":"CI"},{"id":"T11","span":{"begin":658,"end":699},"obj":"CI"},{"id":"T13","span":{"begin":122,"end":133},"obj":"DP"},{"id":"T2","span":{"begin":81,"end":90},"obj":"CI"},{"id":"T3","span":{"begin":275,"end":284},"obj":"CI"},{"id":"T4","span":{"begin":387,"end":414},"obj":"CI"},{"id":"T5","span":{"begin":463,"end":472},"obj":"CI"},{"id":"T6","span":{"begin":748,"end":757},"obj":"CI"},{"id":"T7","span":{"begin":1236,"end":1245},"obj":"CI"},{"id":"T8","span":{"begin":1422,"end":1431},"obj":"CI"},{"id":"T14","span":{"begin":197,"end":208},"obj":"DP"}],"text":"Randomized trial of low-dose peginterferon α-2b plus low and escalating doses of ribavirin in older patients with chronic hepatitis C with high viral load genotype 1.\nElderly patients with chronic hepatitis C cannot tolerate standard combination therapy of peginterferon and ribavirin, which remains the backbone of therapy in many countries, including Japan. The efficacy and safety of low-dose peginterferon α-2b in combination with low and escalating doses of ribavirin in older patients with high viral load genotype 1 were investigated in this randomized controlled trial. Thirty-two patients (age ≥ 60 years) were randomized into standard (group 1) or low (group 2) doses of peginterferon α-2b in combination with low and escalating doses of ribavirin. Patients were evaluated for safety and efficacy of treatment. There was a higher virological response rate in group 1 than in group 2. However, the response in men was higher than in women in the early treatment phase and 24 weeks after treatment (P = 0.008). There was no significant difference between the two groups in the virological response rate in men and women. Completion of therapy was higher in group 2 than in group 1 (31% vs. 13%, P = 0.200). Dose modification of ribavirin was less frequent in group 2 than in group 1 (69% vs. 88%, P = 0.200). These data suggest that combination therapy with low-dose peginterferon plus low and escalating doses of ribavirin may be safer in older patients than that with standard dose peginterferon, without impairing the treatment response."}

{"project":"luoyt2021_800_3","denotations":[{"id":"T1","span":{"begin":81,"end":90},"obj":"CI"},{"id":"T2","span":{"begin":1422,"end":1431},"obj":"CI"},{"id":"T3","span":{"begin":1236,"end":1245},"obj":"CI"},{"id":"T4","span":{"begin":748,"end":757},"obj":"CI"},{"id":"T5","span":{"begin":463,"end":472},"obj":"CI"},{"id":"T6","span":{"begin":275,"end":284},"obj":"CI"},{"id":"T7","span":{"begin":122,"end":133},"obj":"DP"},{"id":"T8","span":{"begin":197,"end":208},"obj":"DP"},{"id":"T9","span":{"begin":387,"end":414},"obj":"CI"},{"id":"T10","span":{"begin":20,"end":47},"obj":"CI"},{"id":"T11","span":{"begin":1366,"end":1388},"obj":"CI"},{"id":"T12","span":{"begin":658,"end":699},"obj":"CI"}],"text":"Randomized trial of low-dose peginterferon α-2b plus low and escalating doses of ribavirin in older patients with chronic hepatitis C with high viral load genotype 1.\nElderly patients with chronic hepatitis C cannot tolerate standard combination therapy of peginterferon and ribavirin, which remains the backbone of therapy in many countries, including Japan. The efficacy and safety of low-dose peginterferon α-2b in combination with low and escalating doses of ribavirin in older patients with high viral load genotype 1 were investigated in this randomized controlled trial. Thirty-two patients (age ≥ 60 years) were randomized into standard (group 1) or low (group 2) doses of peginterferon α-2b in combination with low and escalating doses of ribavirin. Patients were evaluated for safety and efficacy of treatment. There was a higher virological response rate in group 1 than in group 2. However, the response in men was higher than in women in the early treatment phase and 24 weeks after treatment (P = 0.008). There was no significant difference between the two groups in the virological response rate in men and women. Completion of therapy was higher in group 2 than in group 1 (31% vs. 13%, P = 0.200). Dose modification of ribavirin was less frequent in group 2 than in group 1 (69% vs. 88%, P = 0.200). These data suggest that combination therapy with low-dose peginterferon plus low and escalating doses of ribavirin may be safer in older patients than that with standard dose peginterferon, without impairing the treatment response."}